# Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

> **NCT01067989** · PHASE2 · TERMINATED · sponsor: **HaEmek Medical Center, Israel** · enrollment: 22 (actual)

## Conditions studied

- Chemotherapy
- Breast Cancer, Metastatic

## Interventions

- **DRUG:** Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)

## Key facts

- **NCT ID:** NCT01067989
- **Lead sponsor:** HaEmek Medical Center, Israel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** No satisfactory acrual
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01067989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01067989, "Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01067989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*